3-(1-Imidazolyl)benzaldehyde

Catalog No. :
ACGKRY650
CAS No. :
127404-22-2
Molecular Formula :
C10H8N2O
Molecular Weight :
172.19

IUPAC Name:3-(1H-imidazol-1-yl)benzaldehyde

3-(1-Imidazolyl)benzaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10g97%$70.00Login to see priceIn stockIn stock
25g97%$166.00Login to see priceIn stockIn stock
100g97%$601.00Login to see priceIn stockInquiry
500g97%$2915.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(1-Imidazolyl)benzaldehyde
IUPAC Name3-(1H-imidazol-1-yl)benzaldehyde
MDL No.MFCD09836178
Molecular FormulaC10H8N2O
Molecular Weight172.19
SMILESO=CC1=CC=CC(N2C=CN=C2)=C1
InChI KeyCGTQCZGDVDTRDI-UHFFFAOYSA-N
Synonym3-(5-Methoxy-1H-indol-1-yl)benzaldehyde;3-(5-Nitro-1H-indol-1-yl)benzaldehyde;3-(6-(Methoxycarbonyl)-1H-indol-1-yl)benzaldehyde;3-(6-Chloro-1H-indol-1-yl)benzaldehyde;3-(6-Cyano-1H-indol-1-yl)benzaldehyde;3-(6-Fluoro-1H-indol-1-yl)benzaldehyde;3-(6-Methoxy-1H-indol-1-yl)benzaldehyde;3-(6-Nitro-1H-indol-1-yl)benzaldehyde
CAS No.127404-22-2
PubChem CID15650408

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACGKRY650 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACUEAK970 route compound structure diagram
    ACUEAK9703132-99-8 In Stock
  2. Plus
  3. ACDLYM406 route compound structure diagram
    ACDLYM4065587-42-8 In Stock
  4. Then
  5. ACGKRY650 route product structure diagram
    ACGKRY650127404-22-2 In Stock
Inquiry

2. ACGKRY650 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACZLTD689 route compound structure diagram
    ACZLTD689108035-47-8 In Stock
  2. Then
  3. ACGKRY650 route product structure diagram
    ACGKRY650127404-22-2 In Stock
Inquiry

Comments (0)